Affimed (AFMD) has released an update.
Affimed N.V., a clinical-stage immuno-oncology company, has announced that its Annual General Meeting for 2024 will be held on June 26 in Amsterdam. The company is known for developing innovative cancer therapies by harnessing the innate immune system, using its proprietary ROCK platform to create innate cell engagers (ICE) targeting various tumors.
For further insights into AFMD stock, check out TipRanks’ Stock Analysis page.
